Advertisement
GH vs RGEN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a Hold and RGEN is a StrongBuy.
GH in upward trend: price may jump up because it broke its lower Bollinger Band on October 08, 2026
GH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 39 cases where GH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 51 cases where GH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 241 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 175 of 210 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GH as a result. In 66 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for GH turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 33 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
GH moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GH crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-100.352) is normal, around the industry mean (64.450). P/E Ratio (-47.481) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RGEN sees its Stochastic Oscillator ascending out of oversold territory
On October 12, 2026, the Stochastic Oscillator for RGEN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 69 instances where the indicator left the oversold zone. In 53 of the 69 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RGEN as a result. In 68 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
RGEN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 17 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 40 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for RGEN entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.810) is normal, around the industry mean (4.952). RGEN's P/E Ratio (243.257) is considerably higher than the industry average of (36.644). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GH | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 78 | 100 | |
SMR RATING 1..100 | 100 | 88 | |
PRICE GROWTH RATING 1..100 | 36 | 38 | |
P/E GROWTH RATING 1..100 | 56 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GH's Valuation (13) in the Medical Or Nursing Services industry is significantly better than the same rating for RGEN (97) in the Biotechnology industry. This means that GH’s stock grew significantly faster than RGEN’s over the last 12 months.
GH's Profit vs Risk Rating (78) in the Medical Or Nursing Services industry is in the same range as RGEN (100) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's SMR Rating (88) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that RGEN’s stock grew similarly to GH’s over the last 12 months.
GH's Price Growth Rating (36) in the Medical Or Nursing Services industry is in the same range as RGEN (38) in the Biotechnology industry. This means that GH’s stock grew similarly to RGEN’s over the last 12 months.
GH's P/E Growth Rating (56) in the Medical Or Nursing Services industry is somewhat better than the same rating for RGEN (96) in the Biotechnology industry. This means that GH’s stock grew somewhat faster than RGEN’s over the last 12 months.
| GH | RGEN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 84% | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| Declines ODDS (%) | 4 days ago 85% | 15 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 68% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 1 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
- GH’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 5 bullish TA indicator(s).
- GH’s TA Score: 4 bullish, 6 bearish.
- RGEN’s TA Score: 5 bullish, 5 bearish.
Price Growth
GH (@Medical Specialties) experienced а +2.25% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +1.02% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.66%. For the same industry, the average monthly price growth was -7.04%, and the average quarterly price growth was +41.88%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.63%. For the same industry, the average monthly price growth was -3.82%, and the average quarterly price growth was +8.73%.
Reported Earning Dates
GH is expected to report earnings on Nov 05, 2026.
RGEN is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Medical Specialties (-3.66% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+0.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | +0.63% | ||
| DHR - RGEN | 67% Closely correlated | +4.29% | ||
| A - RGEN | 65% Loosely correlated | +2.74% | ||
| BIO - RGEN | 60% Loosely correlated | +1.69% | ||
| MTD - RGEN | 59% Loosely correlated | +2.69% | ||
| TMO - RGEN | 58% Loosely correlated | +0.97% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EPOL | 45.08 | 0.87 | +1.97% |
| iShares MSCI Poland ETF (EPOL) | |||
| RSP | 216.64 | 0.78 | +0.36% |
| Invesco S&P 500 Equal Weight ETF (RSP) | |||
| QCJA | 23.98 | 0.06 | +0.23% |
| FT Vest Nasdaq-100 Conservative Buffer ETF - January (QCJA) | |||
| BSMQ | 23.42 | 0.01 | +0.02% |
| Invesco BulletShares 2026 Municipal Bond ETF (BSMQ) | |||
| MUNX | 23.74 | N/A | N/A |
| AMG GW&K Muni Income ETF (MUNX) | |||